Bepotastine Besilate

Itching, Allergic Conjunctivitis (AC)

Treatment

3 FDA approvals

3 Active Studies for Bepotastine Besilate

What is Bepotastine Besilate

Bepotastine

The Generic name of this drug

Treatment Summary

Bepotastine is a medication that blocks the action of histamine, a chemical involved in allergic reactions. Bepotastine was approved in Japan in 2000 and 2002 to treat allergic rhinitis and urticaria/pruritus, respectively. It can be administered orally or as an ophthalmic solution, and it is sold under the brand names Talion and Bepreve. The ophthalmic solution was approved by the FDA in 2009.

Bepreve

is the brand name

image of different drug pills on a surface

Bepotastine Besilate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Bepreve

Bepotastine

2009

7

Approved as Treatment by the FDA

Bepotastine, otherwise called Bepreve, is approved by the FDA for 3 uses which include Pruritus and Allergic Conjunctivitis (AC) .

Pruritus

Allergic Conjunctivitis (AC)

Itching

Effectiveness

How Bepotastine Besilate Affects Patients

Bepotastine is a drug that works by blocking the histamine 1 (H1) receptor in order to prevent inflammation and allergies. It starts working in about 15 minutes, and its effects can last up to 24 hours. It does not cause side effects like dry mouth or drowsiness, which can be caused by other medications.

How Bepotastine Besilate works in the body

Allergic conjunctivitis is caused by an allergic reaction in the eyes. Bepotastine helps by blocking the histamine that causes itching, stabilizing the mast cells that cause inflammation, and preventing eosinophils from entering the eye and causing further damage.

When to interrupt dosage

The advocated dose of Bepotastine Besilate is contingent upon the diagnosed malady. The quantity of dosage fluctuates as per the approach of administration (e.g. Solution or Solution / drops - Ophthalmic) outlined in the table beneath.

Condition

Dosage

Administration

Itching

, 15.0 mg/mL, 1.5 %

, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Solution - Ophthalmic

Allergic Conjunctivitis (AC)

, 15.0 mg/mL, 1.5 %

, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Solution, Solution - Ophthalmic

Warnings

Bepotastine Besilate Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Bepotastine may interact with Pulse Frequency

There are 20 known major drug interactions with Bepotastine Besilate.

Common Bepotastine Besilate Drug Interactions

Drug Name

Risk Level

Description

Pitolisant

Major

The therapeutic efficacy of Pitolisant can be decreased when used in combination with Bepotastine.

Aclidinium

Minor

Bepotastine may decrease the excretion rate of Aclidinium which could result in a higher serum level.

Acrivastine

Minor

Bepotastine may decrease the excretion rate of Acrivastine which could result in a higher serum level.

Albutrepenonacog alfa

Minor

Bepotastine may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.

Almasilate

Minor

Bepotastine may decrease the excretion rate of Almasilate which could result in a higher serum level.

image of a doctor in a lab doing drug, clinical research

Bepotastine Besilate Novel Uses: Which Conditions Have a Clinical Trial Featuring Bepotastine Besilate?

19 active clinical trials are currently being conducted to determine the potential of Bepotastine Besilate for the amelioration of Itch.

Condition

Clinical Trials

Trial Phases

Allergic Conjunctivitis (AC)

1 Actively Recruiting

Phase 2

Itching

2 Actively Recruiting

Phase 3, Not Applicable

Bepotastine Besilate Reviews: What are patients saying about Bepotastine Besilate?

5

Patient Review

5/1/2010

Bepotastine Besilate for Allergic Conjunctivitis

This has been a game-changer for my son. He's only 8, but he had such severe seasonal allergies that it was really impacting his quality of life. This medication has helped him so much.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about bepotastine besilate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of BEPREVE eye drops?

"Symptoms include an unpleasant taste in the mouth, headache, eye irritation, stuffy nose, and sore throat."

Answered by AI

What is BEPREVE prescribed for?

"BEPREVE is a medicine that is used to treat itching that is caused by allergies."

Answered by AI

Do you need a prescription for BEPREVE?

"Bepotastine (Bepreve) is not available over the counter and requires a prescription from a healthcare provider. If you're looking for something over the counter, you may want to try Pataday (olopatadine) or Zaditor (ketotifen), which work similarly to bepotastine (Bepreve)."

Answered by AI

What is bepotastine besilate used for?

"Bepotastine besilate eye drops are used to treat allergic conjunctivitis, which is caused by the body overreacting to substances that it is otherwise harmless. The drops work by preventing the effects of certain inflammatory substances that are produced naturally by the cells in your eyes."

Answered by AI

Clinical Trials for Bepotastine Besilate

Image of Johns Hopkins Bayview Medical Center in Baltimore, United States.

VR-Enhanced PMR for Post-Burn Symptoms

18+
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn whether progressive muscle relaxation (PMR), delivered either alone or enhanced with virtual reality (VR), can help treat chronic symptom, such as pain, itch, anxiety, sleep disturbances, and fatigue, in adult burn survivors. The main questions it aims to answer are: * Does VR-enhanced PMR (VR-PMR) reduce chronic pain, anxiety, itch, sleep disturbances, and fatigue more effectively than standard PMR? * Is VR-PMR a feasible and acceptable self-administered home-based intervention for burn survivors? Researchers will compare two self-administered intervention conditions, VR-enhanced PMR and standard PMR, using a randomized to sequence crossover design to see if VR technology enhances the therapeutic effects of PMR on chronic symptom management in burn survivors. Participants will: * Complete home-based sessions of VR-enhanced PMR * Complete home-based sessions of standard PMR * Report symptoms such as pain, itch, anxiety, sleep disturbances, and fatigue throughout the study * Use VR equipment provided for the intervention period (during the VR-PMR arm)

Recruiting
Has No Placebo

Johns Hopkins Bayview Medical Center

Sheera Lerman Zohar, PhD